Last updated on April 18, 2014 at 15:51 EDT

Heptares to Present at GDDIS 2012 (22-23 October) and the Boston Biotech Conference NY CEO Meeting (1-2 November)

October 18, 2012

WELWYN GARDEN CITY, England and BOSTON, October 18, 2012 /PRNewswire/ –

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its
President, Dan Grau, will represent the Company at the 2nd Annual Global Discovery to
Development Innovation Summit (GDDIS 2012 [http://www.gddis.com ]) which takes place at
The Westin, Philadelphia, PA, USA (22-23 October 2012).

Mr Grau will also participate on a panel discussion on Rare Diseases at the Boston
Biotech Conference New York CEO Meeting
[http://bbbiotechconference.com/conference-details.php?id=13 ] taking place at Apella in
New York City, NY, USA (1-2 November, 2012).

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G protein-coupled
receptors), a super-family of drug targets linked to a wide range of human diseases. Our
pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have
raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and
Takeda Ventures.

Heptares is pioneering the application of structure-based drug design to the GPCR
superfamily of targets and is focused on creating molecules that modulate high-value, yet
historically undruggable or challenging, GPCRs. Our platform incorporates proprietary
technologies for engineering stabilised GPCRs in their natural pharmacological
conformations, identifying previously unknown chemistries for GPCR protein-drug
interactions, and deploying advanced fragment-based approaches to GPCR target space for
the first time.

Using this approach, we have generated a broad pipeline of drug candidates for the
treatment of serious disorders, including Alzheimer’s disease, Parkinson’s disease,
schizophrenia, depression, chronic insomnia, addiction disorders, migraine and diabetes.
For more information about Heptares, please visit http://www.heptares.com.

SOURCE Heptares Therapeutics

Source: PR Newswire